The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: A technology assessment

Health Technology Assessment

Volumn 6, Issue 6, 2002, Pages

  O'Meara, S ^a   Riemsma, R ^a   Shirran, L ^a   Mather, L ^a   Ter Riet, G ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

ANTHROPOMETRIC PARAMETERS; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INFORMATION PROCESSING; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION RISK; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION; BIOMEDICAL TECHNOLOGY ASSESSMENT; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; RANDOMIZED CONTROLLED TRIAL;

APPETITE DEPRESSANTS; COST-BENEFIT ANALYSIS; CYCLOBUTANES; HUMANS; OBESITY; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 0036091338     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta6060     Document Type: Review

References (76)

1. Obesity
2. Obesity in Britain: Gluttony or sloth?
3. Familial trends of obesity through three generations: The Belgian-Luxembourg child study
4. Obesity: Internal medicine, obstetric and gynecological problems related to overweight
5. Childhood predictors of adult obesity: A systematic review
6. The influence of smoking cessation on the prevalence of overweight in the United States
7. Pathophysiology of obstructive sleep apnoea
8. Sleep-disordered breathing and obesity
9. The prevalence of obstructive sleep apnoea in an obese female population
10. The sleep apnoea syndrome in obesity: Risk of sudden death
11. Waist circumference action levels in the identification of cardiovascular risk factors: Prevalence study in a random sample
12. The influence of body fat distribution on the incidence of diabetes mellitus
13. Greater influence of central distribution of adipose tissue on incidence of non-insulin diabetes in women than in men
14. Beneficial effects of modest weight loss
15. Change in body weight and longevity
16. Larger fluctuations in body weight during young adulthood and twenty-five-year risk of coronary death in men
17. Variability of body weight and health outcomes in the Framingham population
18. Body weight change, all-cause mortality, and cause-specific mortality in the multiple risk factor intervention trial
19. Does weight cycling present a health risk?
20. Periodic health examination, 1999 update. 1. Detection, prevention and treatment of obesity
21. Clinical management of overweight and obese patients with particular reference to the use of drugs
22. Valvular heart disease associated with fenfluramine-phentermine
23. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity
24. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
25. Effects of sibutramine on resting metabolic rate and weight loss in overweight women
26. Sibutramine in weight control: A dose-ranging, efficacy study
27. Sibutramine produces dose-related weight loss
28. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity
29. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females
30. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study
31. A comparison of sibutramine and dexfenfluramine in the treatment of obesity
32. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
33. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
34. Six-month treatment of obesity with sibutramine 15 mg; A double-blind, placebo-controlled monocenter clinical trial in a Hispanic population
35. Cost-utility analysis of sibutramine
36. Randomised placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity
37. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
38. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
39. Assessing impact of weight on quality of life
40. Variations in population health status: Results from a United Kingdom National Questionnaire survey
41. Intent-to-treat analysis for longitudinal studies with drop-outs
42. Orlistat and weight loss
43. Orlistat and weight loss - Reply
44. Improving the quality of reporting of randomized controlled trials - The CONSORT statement
45. Establishing a standard definition for child overweight and obesity worldwide: International survey
46. Adolescent obesity, a need for greater awareness and improved treatment
47. Effective management of obesity
48. Helping obese youngsters lose weight: What works ... What doesn't?
49. Drug therapy for obesity in the elderly
50. An overview of age-specific pharmacokinetics and pharmacodynamics
51. Sibutramine pharmacokinetics in young and elderly healthy subjects
52. Gender-specific aspects of obesity
53. Weight change as a risk factor for clinical diabetes mellitus in women
54. Control group characteristics and study outcomes: Empirical data from a study on mortality of patients with type 2 diabetes mellitus in Dutch general practice
55. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years
56. Deriving a preference-based single index from the UK SF-36 Health Survey
57. The cost of obesity in the United Kingdom